At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL (NCT05050630) | Affiliated Hospital to Academy of Military Medical Sciences | 2021-08-01 |
Track At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.